MBRX News and Press, Moleculin Biotech Inc. From 11/10/23

2023-11-10 14:16:55 ET More on Moleculin Biotech Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech For further details see: Moleculin Biotech Q3 2023 Earning...

2023-11-10 10:37:05 ET Major earnings expected before the bell on Monday include: Auxly Cannabis Group ( OTCQB:CBWTF ) Capital Product Partners ( CPLP ) Sundial Growers ( SNDL ) Tower Semiconductor ( TSEM ) Tyson Foods ( TSN ) For further deta...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Moleculin Biotech Inc. (MBRX) is expected to report $-0.2 for Q3 2023

Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast PR Newswire HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmace...

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases PR Newswire – Poster Presented at the 2023 Conn...

2023-10-24 07:45:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to know about! Moving stocks this morning are a delisting notice, earnings resu...

Moleculin to Participate in the Virtual Investor Ask the CEO Conference PR Newswire Live video webcast with Walter Klemp, CEO and Jonathan Foster , Executive VP and CFO of Moleculin on Tuesday, October 25 th at 12:00 PM ET HOUSTON , Oct. ...

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Phase 1B portion of Phase 1B /2 study demonstrated preliminary CR/...

2023-09-28 07:25:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re checking out the biggest pre-market stock movers on Friday with a dive into all of the latest market stories! Moving stocks this morning are clinical trials, new partnerships, ...